Related Experiment Videos
Ticlopidine induced cholestatic jaundice
Singapore Medical Journal
|March 1, 1997
Insights
Ticlopidine hydrochloride, an antiplatelet drug, may rarely cause cholestatic jaundice. This case report highlights a rare but serious side effect of this commonly used medication.
Area of Science:
- Pharmacology
- Hepatology
- Clinical Medicine
Background:
- Ticlopidine hydrochloride is a widely used antiplatelet medication.
- It demonstrates significant efficacy in preventing stroke recurrence, potentially exceeding that of aspirin.
- Common side effects include gastrointestinal disturbances and blood dyscrasias.
Observation:
- A rare case of ticlopidine-induced cholestatic jaundice is presented.
- This adverse event is infrequently reported in medical literature.
- The patient experienced jaundice as a consequence of ticlopidine hydrochloride administration.
Findings:
- Ticlopidine hydrochloride, despite its benefits, carries a risk of rare but severe hepatotoxicity.
- Cholestatic jaundice is an identified, albeit uncommon, adverse reaction.
- The case underscores the importance of monitoring liver function in patients on ticlopidine therapy.
Implications:
- Clinicians should be aware of the potential for ticlopidine-induced cholestatic jaundice.
- Early recognition and management are crucial for patients developing jaundice while on ticlopidine.
- This case contributes to the understanding of rare adverse drug reactions in antiplatelet therapy.
Abstract:
Ticlopidine hydrochloride (Ticlid) has been increasingly used as an antiplatelet agent. Some studies showed that it has higher efficacy in reducing stroke recurrence when compared to conventional aspirin. Side effects like gastrointestinal disturbances and blood dyscrasias are common but ticlopidine-induced cholestatic jaundice has been reported only rarely. We present a case report on a patient who has ticlopidine-induced cholestatic jaundice.